IN THE UNITED STATES BANKRUPTCY COURT FOR THE SOUTHERN DISTRICT OF TEXAS HOUSTON DIVISION

)	
In re:)	Chapter 11
Sorrento Therapeutics, Inc., et al., 1)	Case No. 23-90085 (CML)
Debtors.)	Re: Docket No. 2129
)	

NOTICE OF FILING OF PROPOSED ORDER REGARDING DEBTORS' MOTION FOR ENTRY OF AN ORDER AUTHORIZING THE (I) ASSUMPTION OF CERTAIN EXECUTORY CONTRACTS AND (II) THE ASSUMPTION AND ASSIGNMENT OF CERTAIN EXECUTORY CONTRACTS

[Relates to Dkt. No. 2129]

PLEASE TAKE NOTICE that on April 5, 2024, Sorrento Therapeutics, Inc. ("Sorrento") filed its *Debtors' Motion for Entry of an Order Authorizing the (I) Assumption of Certain Executory Contracts and (II) The Assumption and Assignment of Certain Executory Contracts* (the "Motion") [Dkt. No. 2129].

PLEASE TAKE FURTHER NOTICE that attached hereto as Exhibit A is Sorrento's proposed form of order.

PLEASE TAKE FURTHER NOTICE that attached hereto as **Exhibit B** is a redline of the exhibits to the proposed form of order.²

PLEASE TAKE FURTHER NOTICE that copies of the filings in these chapter 11 cases can be obtained through the Bankruptcy Court's electronic case filing system at https://ecf.txsb.uscourts.gov.

[Remainder of Page Intentionally Left Blank]

¹ The Post Effective Date Debtor entities in these chapter 11 cases, along with the last four digits of each entity's federal tax identification number, are: Sorrento Therapeutics, Inc. (4842) and Scintilla Pharmaceuticals, Inc. (7956). The Post Effective Date Debtors' service address is: 9380 Judicial Drive, San Diego, CA, 92121.

² The revised form of proposed order specifically denotes the removal of the Eastgate Bend Two lease from the schedule of Assigned Contracts.

Dated: August 2, 2024 Respectfully submitted,

By: /s/ Ryan Manns

Ryan Manns (SBT 24041391)

Jason I. Blanchard (SBT 24130197)

NORTON ROSE FULBRIGHT US LLP

1301 McKinney Street, Suite 5100

Houston, TX 77010

Telephone: (713) 651-5151 Facsimile: (713) 651-5246

Email: ryan.manns@nortonrosefulbright.com jason.blanchard@nortonrosefulbright.com

Counsel to David Weinhoffer, Liquidation Trustee of the Sorrento Therapeutics, Inc. et al., Liquidation Trust

CERTIFICATE OF SERVICE

I, Ryan Manns, hereby certify that on the 2nd day of August, 2024, a copy of the foregoing *Notice* was served via Electronic Case Filing System for the United States Bankruptcy Court for the Southern District of Texas.

By: <u>/s/ Ryan Manns</u> Ryan Manns

EXHIBIT A

IN THE UNITED STATES BANKRUPTCY COURT FOR THE SOUTHERN DISTRICT OF TEXAS HOUSTON DIVISION

)
In re:) Chapter 11
)
Sorrento Therapeutics, Inc., et al., 1) Case No. 23-90085 (CML)
)
Debtors.) Re: Docket No.
)

ORDER AUTHORIZING THE (I) ASSUMPTION OF CERTAIN EXECUTORY CONTRACTS AND (II) THE ASSUMPTION AND ASSIGNMENT OF CERTAIN EXECUTORY CONTRACTS

The Debtors filed their motion (the "Motion")² for entry of an order (this "Order") authorizing (i) the assumption of certain unexpired contracts (the "Assumed Contracts"), and (ii) the assumption and assignment of certain unexpired contracts (the "Assigned Contracts"). The Court has jurisdiction over the Motion pursuant to 28 U.S.C. § 1334. Venue is proper pursuant to 28 U.S.C. §§ 1408 and 1409. The Motion is a core proceeding pursuant to 28 U.S.C. § 157(b)(2), and the Court may enter a final order on the Motion. The relief requested in the Motion is in the best interests of the Debtors, their estates, stakeholders, and other parties in interest and the Debtors gave sufficient and proper notice of the Motion and related hearings. Upon consideration of the Motion and any arguments in support of the Motion, the Court finds that good cause exists to grant the requested relief. It is therefore ORDERED THAT:

1. Pursuant to sections 105(a) and 365 of the Bankruptcy Code the Debtors hereby (i) assume the Assumed Contracts (as set forth on Exhibit A hereto) and (ii) assume and assign the Assigned Contracts (as set forth on Exhibit B hereto), in each case effective upon the payment to the applicable counterparty of the applicable cure amount (if any) identified on Exhibit A or Exhibit B, as applicable (the "Cure Costs").

¹ The Post Effective Date Debtor entities in these chapter 11 cases, along with the last four digits of each entity's federal tax identification number, are: Sorrento Therapeutics, Inc. (4842) and Scintilla Pharmaceuticals, Inc. (7956). The Post Effective Date Debtors' service address is: 9380 Judicial Drive, San Diego, CA, 92121.

² Capitalized terms used but not otherwise defined herein have the meanings ascribed to them in the Motion.

Case 23-90085 Document 2338-1 Filed in TXSB on 08/02/24 Page 3 of 5

2. The Cure Costs may be paid by the Purchaser (as defined in the Sale Order) or a designee

thereof. If the Cure Costs are not paid within three business days after entry of this Order (or such later time

as agreed to in writing by the applicable contract counterparty), the applicable Assumed Contract or

Assigned Contract shall be deemed rejected as of such date.

3. Notwithstanding anything in the Debtors' chapter 11 plan to the contrary, the Assumed

Contracts and Assigned Contracts shall not be deemed rejected upon the Plan's effective date, but rather

shall be assumed, assigned, or rejected in accordance with the terms of this Order.

4. The Debtors are authorized to take all actions necessary or appropriate to carry out the relief

granted in this Order.

5. This Court retains exclusive jurisdiction with respect to all matters arising from or related

to the enforcement of this Order.

SIGNED:

CHRISTOPHER M. LOPEZ UNITED STATES BANKRUPTCY JUDGE

2

Exhibit A - Assumed Contracts

Combined Country	Description of Contract on Land	Cure
Contract Counterparty	Description of Contract or Lease	Amount
Wex Health, Inc.	COBRA Administrative Services Agreement	
Alliant Insurance Services, Inc.	Broker Services Agreement	
UnitedHealthcare Insurance Company	Group Dental Policy	
UnitedHealthcare Benefits Plans of California	Medical and Hospital Group Subscriber Agreement	_
UnitedHealthcare Insurance Company	UnitedHealthcare Select Plus (for Plan CUI4)	_
UnitedHealthcare Insurance Company	UnitedHealthcare PPO Dental	
UnitedHealthcare Insurance Company		
' '	UnitedHealthcare Select Plus (for HSA Plan DIWW)	
UnitedHealthcare of California	Medical and Hospital Group Subscriber Agreement	
	Harmony HMO Renewal Contract (288)	
UnitedHealthcare of California	Medical and Hospital Group Subscriber Agreement	
	HMO Renewal Contract (2X0)	
UnitedHealthcare Insurance Company	UnitedHealthcare Vision	
UnitedHealthcare Insurance Company	Group Policy	
Total Cure Costs	1	\$0.00

Exhibit B - Assigned Contracts

Contract Counterparty	Assignee	Description of Contract or Lease	Cure Amount
Diagnostic Consulting Network, LLC dba DCN Diagnostics	Virex Health, Inc.	Feasibility and Prototyping Phase Proposal	_
Diagnostic Consulting Network, LLC dba DCN Diagnostics	Virex Health, Inc.	Feasibility and Prototyping Phase Proposal	
Diagnostic Consulting Network, LLC dba DCN Diagnostics	Virex Health, Inc.	Feasibility and Prototyping Phase Proposal	
Diagnostic Consulting Network, LLC dba DCN Diagnostics	Virex Health, Inc.	Confidentiality Agreement	
Gener8, LLC	Virex Health, Inc.	Engineering Services Agreement	\$119,764
Gener8, LLC	Virex Health, Inc.	Mutual Confidentiality Agreement	
The Scripps Research Institute	Vivasor, Inc.	License Agreement for Phage Display Vectors	_
Total Cure Costs	•	•	\$119,764

EXHIBIT B

Exhibit A - Assumed Contracts

Contract Counterparty	Description of Contract or Lease	Cure Amount
Wex Health, Inc.	COBRA Administrative Services Agreement	_
Alliant Insurance Services, Inc.	Broker Services Agreement	
UnitedHealthcare Insurance Company	Group Dental Policy	
UnitedHealthcare Benefits Plans of California	Medical and Hospital Group Subscriber Agreement	
UnitedHealthcare Insurance Company	UnitedHealthcare Select Plus (for Plan CUI4)	
UnitedHealthcare Insurance Company	UnitedHealthcare PPO Dental	
UnitedHealthcare Insurance Company	UnitedHealthcare Select Plus (for HSA Plan DIWW)	
UnitedHealthcare of California	Medical and Hospital Group Subscriber Agreement Harmony HMO Renewal Contract (288)	
UnitedHealthcare of California	Medical and Hospital Group Subscriber Agreement HMO Renewal Contract (2X0)	
UnitedHealthcare Insurance Company	UnitedHealthcare Vision	
UnitedHealthcare Insurance Company	Group Policy	
Total Cure Costs	,	\$0.00

Exhibit B - Assigned Contracts

Contract Counterparty	Assignee	Description of Contract or Lease	Cure Amount
Diagnostic Consulting Network, LLC	Virex Health, Inc.	Feasibility and Prototyping Phase Proposal	
dba DCN Diagnostics			
Diagnostic Consulting Network, LLC	Virex Health, Inc.	Feasibility and Prototyping Phase Proposal	
dba DCN Diagnostics			
Diagnostic Consulting Network, LLC	Virex Health, Inc.	Feasibility and Prototyping Phase Proposal	
dba DCN Diagnostics			
Diagnostic Consulting Network, LLC	Virex Health, Inc.	Confidentiality Agreement	
dba DCN Diagnostics			
Gener8, LLC	Virex Health, Inc.	Engineering Services Agreement	\$119,764
Gener8, LLC	Virex Health, Inc.	Mutual Confidentiality Agreement	
The Scripps Research Institute	Vivasor, Inc.	License Agreement for Phage Display Vectors	_
Eastgate Bend Two	Vivasor, Inc.	November 27, 2012 Lease (as Amended)	
Total Cure Costs			\$119,764

Summary report:		
Litera Compare for Word 11.4.0.111 Document comparison done on		
8/2/2024 4:34:42 PM		
Style name: Default Style		
Intelligent Table Comparison: Active		
Original filename: Microsoft Word - 39633840_4_Sorren	to - Motion to	
Assume and Assign Virex Health Contracts.docx		
Modified filename: Sorrento - Order Approving Assumption	ion and	
Assignment.docx		
Changes:		
Add	0	
Delete	1	
Move From	0	
Move To	0	
Table Insert	0	
Table Delete	1	
Table moves to	0	
Table moves from	0	
Embedded Graphics (Visio, ChemDraw, Images etc.)	0	
Embedded Excel	0	
Format changes	0	
Total Changes:	2	